57 results
8-K
EX-99.1
BMEA
Biomea Fusion Inc
1 Apr 24
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
4:06pm
of diabetes.”
COVALENT-112 is a randomized, placebo-controlled, double-blind Phase II study (n=150) designed to examine the safety, efficacy … label portion (n=40) will also examine the safety, efficacy, and durability of BMF-219 at two oral dose levels, 100 mg and 200 mg, for 12 weeks
8-K
EX-99.1
BMEA
Biomea Fusion Inc
1 Apr 24
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:05pm
and examine the safety and efficacy of BMF-219 at two oral dose levels, 100 mg and 200 mg, for 12 weeks of treatment followed by a 40 week off-treatment
8-K
EX-99.1
ezrgd775xh75wc
7 Mar 24
Other Events
4:02pm
8-K
EX-99.3
00zf0zs2
7 Mar 24
Other Events
4:02pm
8-K
EX-99.4
7c0a0
7 Mar 24
Other Events
4:02pm
8-K
EX-99.2
fvg8h
7 Mar 24
Other Events
4:02pm
8-K
EX-99.1
mb3zlipv5 9ug11
30 Oct 23
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:05pm
8-K
EX-99.1
jvse2tmo twh
31 Jul 23
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:08pm
8-K
EX-99.1
dqcnz3ulhprg6bsrw8f
25 Jul 23
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
4:05pm
8-K
EX-99.1
kyvr owcg
2 May 23
Other Events
5:01pm
8-K
EX-99.1
vjmki rf08ev9l
2 May 23
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights
4:11pm
8-K
EX-1.1
5b73li
3 Apr 23
Biomea Fusion Announces Proposed Public Offering of Common Stock
4:06pm
424B5
qimjvwq sfex7i
30 Mar 23
Prospectus supplement for primary offering
4:06pm